How do I buy SI-BONE, Inc. Common Stock (SIBN) stock?

Buying SI-BONE, Inc. Common Stock (SIBN) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "SIBN", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy SIBN by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for SIBN on Gotrade?

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in SI-BONE, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does SI-BONE, Inc. Common Stock (SIBN) pay dividends?

At the moment, SI-BONE, Inc. Common Stock (SIBN) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track SIBN's performance via the price chart in the Gotrade app.

Is buying SIBN on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy SIBN?

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours. Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

How do I tell if SIBN is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

SI-BONE, Inc. Common Stock (SIBN) Stock Price Today & Analysis

% positive news of 10 articles

published over the past 14 days

Latest news

Zacks Investment Research

Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?

NeutralSIBNAugust 25, 2026

Zacks Investment ResearchNeutral

Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?

SIBN

Zacks Investment Research

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade

NeutralSIBNAugust 24, 2026

Zacks Investment ResearchNeutral

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade

SIBN

Zacks Investment Research

Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?

NeutralSIBNAugust 6, 2026

Zacks Investment ResearchNeutral

Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?

SIBN

Zacks Investment Research

Wall Street Analysts Predict a 71.13% Upside in Si-Bone (SIBN): Here's What You Should Know

NeutralSIBNJune 1, 2026

Zacks Investment ResearchNeutral

Wall Street Analysts Predict a 71.13% Upside in Si-Bone (SIBN): Here's What You Should Know

SIBN

Zacks Investment Research

How Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27%

NeutralSIBNMay 15, 2026

Zacks Investment ResearchNeutral

How Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27%

SIBN

MarketBeat

SiBone Q1 Earnings Call Highlights

NeutralSIBNMay 12, 2026

MarketBeatNeutral

SiBone Q1 Earnings Call Highlights

SIBN

Zacks Investment Research

Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates

NeutralSIBNMay 12, 2026

Zacks Investment ResearchNeutral

Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates

SIBN

About SI-BONE, Inc. Common Stock

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

SectorHealthcare

IndustryMedical Devices

Employees376

CEOMs. Laura A. Francis MBA

IPO DateOct 17, 2018

HeadquartersSanta Clara, CA

Key Executives

Name	Title	Year Born
Mr. Jeffrey W. Dunn	Executive Chairman	1956
Ms. Laura A. Francis MBA	CEO & Director	1967
Mr. Anshul Maheshwari	COO & CFO	1980
Mr. Michael A. Pisetsky J.D.	Chief Business & Legal Affairs Officer, Secretary and General Counsel	—
Mr. Anthony J. Recupero	Advisor	1960
Dr. Scott A. Yerby Ph.D.	Senior VP of Engineering & CTO	1968
Mr. Saqib Iqbal	Vice President of Financial Planning & Analysis and Investor Relations	—
Mr. Ian Bailey	Vice President of Product & Marketing	—
Dr. Daniel Joseph Cher M.D.	Senior Vice President of Clinical, Regulatory Affairs & Quality	1965
Dr. W. Carlton Reckling M.D.	Chief Medical Officer & VP of Medical Affairs	1963

Fundamentals

Valuation

Market cap$833.18M

Price-to-sales ratio3.89

Price-to-book value4.55

Price-earnings ratio-56.70

Return on Equity-10.00%

Return on Sales-7.00%

Return on Assets-7.00%

PEG ratioN/A

Earnings Per Share

Earnings Per Share$-0.34

Income Statement

Average volume558,742

EBITDA$-8.03M

1 year high (52w)$21.89

1 year low (52w)$11.48

Dividend

Ex dividend dateN/A

Dividend amount$0.00

Dividend yield0.00%

Last payment dateN/A

Dividend yield (TTM)N/A

Next earnings reportN/A

Solvency

Debt-to-equity ratioN/A

Technicals

OscillatorsBuy5 Indicators

Moving AveragesStrong Buy12 Indicators

What the experts say

3 Wall Street Analyst Ratings

BUY

100% Buy

0% Hold

0% Sell

Target price

$22.67

Est return

21.93%

Truist Securities

Richard Newitter

Buy

Target price

$23.00

Est return

22.54%

TD Cowen

Mathew Blackman

Buy

Target price

$20.00

Est return

6.55%

UBS

Patrick Wood

Buy

Target price

$25.00

Est return

33.19%

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021									-1.6	+0.7	-17.1	+18.5
2022	-13.5	+11.4	+3.5	-12.1	-26.4	-9.2	-1.2	+20.2	+5.2	+11.5	-34.3	+7.3
2023	+27.9	+16.0	-1.7	+14.0	+11.4	+6.9	-5.6	-10.9	-6.1	-19.7	+9.8	+11.5
2024	-3.0	-15.9	-4.2	-9.6	-3.2	-9.5	+17.8	+12.0	-12.3	+1.3	+0.5	+4.9
2025	+20.3	+6.5	-20.1	-2.8	+38.2	-0.2	-7.0	-4.1	-10.5	+3.9	+29.3	+4.5
2026	-16.2	-5.2	-19.6	-4.8	+6.7	+17.7	+5.7	+3.1	-1.7

SI-BONE, Inc. Common Stock (SIBN) Stock

Fundamentals

Recent news

Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?

Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade

Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?

Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?

Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

Technicals

Analyst Ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?

Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade

Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?

Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?

Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

SiBone Q2 Earnings Call Highlights

SiBone Q2 Earnings Call Highlights

Bears are Losing Control Over Si-Bone (SIBN), Here's Why It's a 'Buy' Now

Bears are Losing Control Over Si-Bone (SIBN), Here's Why It's a 'Buy' Now

Wall Street Analysts Predict a 71.13% Upside in Si-Bone (SIBN): Here's What You Should Know

Wall Street Analysts Predict a 71.13% Upside in Si-Bone (SIBN): Here's What You Should Know

How Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27%

How Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27%

SiBone Q1 Earnings Call Highlights

SiBone Q1 Earnings Call Highlights

Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates

Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates

About SI-BONE, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Solvency

Technicals

What the experts say

Seasonality

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade